Summary
A LEGAL TACTIC that lets big pharmaceutical companies make payments to other drug makers to delay the entry of low-cost generic competition is under fire from politicians and the Federal Trade Commission, who seek to restrict or eliminate such arrangements. [...] the bills that propose limiting or killing the practice could have a harmful effect on pharmaceutical companies, said Sheila F. McShane, a partner with the Newark law firm Gibbons P.C., who has represented research drug firms in patent litigation.
See the full content of this document
Extract
Pharma at Crossroads in Patent Protection
A LEGAL TACTIC that lets big pharmaceutical companies make payments to other drug makers to delay the entry of low-cost generic competition is under fire from politicians and the Federal T...
See the full content of this document
Sponsored links
